In the spectrum of targeted therapies for chronic myeloid leukemia, imatinib pioneered the era of BCR-ABL inhibition, but some patients develop resistance due to mutations in the kinase domain. Dasatinib Powder, chemically a small molecule kinase inhibitor with oral activity, belongs to the second-generation BCR-ABL tyrosine kinase inhibitors. Unlike imatinib's single-target approach, dasatinib exhibits dual inhibitory activity against both BCR-ABL and SRC family kinases, maintaining inhibitory activity against 18 imatinib-resistant BCR-ABL mutant strains (except T315I) in vitro.
🧬 Pyrimidinethiazole biheterocyclic flexible framework
Dasatinib Powder has the complete molecular formula C₂₂H₂₆ClN₇O₂S and a relative molecular mass of 488.01. Single-crystal diffraction patterns show a linear, extended stereoconformation of the complete reduced pyrimidine six-membered heterocycle, the central thiazole five-membered ring, the terminal chlorotoluamide, and the side chain hydroxyethylpiperazine. The molecule contains no chiral carbons and no racemic stereoimpurities interfering with target recognition. The purity of the complete active heterocycle configuration remains consistently above 99.8%. The entire molecule exhibits clear functional partitioning. Multiple nitrogen and sulfur atoms within the central thiazole ring form a multi-layered hydrogen-bonded network with the polar residues of glutamine and leucine in the kinase hinge region. This network forms the core framework for competitively occupying ATP substrate binding sites and anchoring the kinase catalytic pocket for extended periods.
The left-side pyrimidine ring connects to a hydrophilic side chain of hydroxyethylpiperazine, balancing the overall water solubility of the molecule and improving diffusion efficiency in blood and bone marrow interstitial fluid. The right-side chlorotoluamide hydrophobic aromatic side chain fills the narrow, elongated hydrophobic cavity outside the kinase, precisely distinguishing the cavity size of BCR-ABL from other irrelevant kinases, significantly reducing the risk of broad-spectrum off-target inhibition. The three structural segments work in synergy to achieve potent blocking of dual-conformation BCR-ABL and simultaneous inhibition of multiple oncogenic kinases. Disruption of any one of these structural segments significantly inhibits leukemia clonal proliferation and tumor invasion blocking activity.
Most first-generation ABL kinase inhibitors only bind to the resting conformation of the kinase, resulting in a significant decrease in inhibitory activity in in vitro incubation systems with drug-resistant leukemia cells. This product, however, has a dual heterocyclic flexible framework that can bind to both the open and closed resting conformations of the ABL kinase. Kinetic assays show that Dasatinib Powder BCR-ABL IC50 = 0.6–0.8 nM and SRC IC50 = 0.5 nM, exhibiting an inhibitory potency 325 times that of imatinib. It covers the vast majority of imatinib-resistant mutations, including Y253H, E255K, and F317L, with only the T315I mutation showing an inhibitory gap. The combination of a pyrimidinthiazole dual heterocyclic structure and a piperazine hydrophilic side chain achieves nanomolar-level potent efficacy and overcomes kinase mutation resistance-a core physicochemical advantage that single-target inhibitors cannot achieve.
The pyrimidine-thiazole aromatic conjugated system exhibits excellent chemical stability, lacking easily hydrolyzable ester bonds and oxidation-sensitive unsaturated side chains. It is resistant to ring cracking and side-chain amino chain degradation during room temperature and light-protected storage. Long-term placement in cultures of chronic myeloid leukemia stem cells, solid tumor epithelial cells, and mast cells does not result in cross-linking, precipitation, or aggregation. It eliminates the need for additional solubilizers and stabilizers when constructing long-term drug-resistant in vitro pathological models of hematologic malignancies, reducing interference from exogenous reagents in the immunofluorescence detection signal of kinase-phosphorylated proteins. A set of molecular binding kinase kinase assays showed that homologous derivatives with the hydrogen bond sites of the intermediate thiazole ring exhibited a twelve-fold increase in dissociation rate with BCR-ABL and SRC kinases, with almost complete loss of tumor cell proliferation inhibitory activity. The thiazole five-membered heterocyclic hydrogen bond network is an irreplaceable core functional unit for long-term locking of multi-kinase catalytic centers.
The hydrophilic side chain of hydroxyethylpiperazine moderately improves the molecular solubility. Dasatinib powder is almost insoluble in pure water, but its solubility in DMSO at room temperature reaches 25.3 mg/mL. No flocculent precipitation occurs in the high-concentration tumor cell incubation stock solution, eliminating the need for a high proportion of solubilizer to maintain uniform molecular dispersion. With a lipid-water partition coefficient LogP=2.21, its moderate lipid solubility allows for penetration through both the bone marrow stromal cell membrane and the phospholipid bilayer of solid tumor epithelial cells. A single component can simultaneously construct a triple composite pathological model of imatinib-resistant chronic myeloid leukemia, SRC-driven solid tumor invasion, and c-KIT mutant mast cell proliferation, reducing the need for multiple active ingredients and minimizing variable interference.
⚙️ Kinase Regulation Logic Based on Dual Target Inhibition
Dasatinib Powder, relying on its amphiphilic, balanced pyrimidine thiazole bicyclic small molecule backbone, freely penetrates the bone marrow stroma, leukemia stem cells, and solid tumor epithelial cell membranes. The intact molecule is directionally enriched in intracellular regions containing multiple tyrosine kinases, including BCR-ABL, SRC, and c-KIT. The entire regulatory process consists of four progressive pathways: competitive occupancy of ATP pockets, multi-kinase phosphorylation blockade, downstream proliferation pathway silencing, and inhibition of tumor cell migration and invasion. It can simultaneously bind to kinase activity and resting conformation, effectively mitigating signal escape caused by first-generation TKI resistance mutations, unlike single-target inhibitors that only bind to the resting conformation and are prone to treatment failure.
In human Philadelphia chromosome-positive leukemia cells, a translocation of chromosome 9/22 generates a BCR-ABL fusion kinase, which continuously and autonomously phosphorylates and activates the RAS/RAF, PI3K/AKT, and JAK/STAT proliferation pathways, driving the unlimited clonal expansion of hematopoietic stem cells. In solid tumors, overactivation of SRC family kinases remodels cell adhesion molecules, enhancing tumor migration and distant metastasis. Mast cells and gastrointestinal stromal tumors rely on mutated c-KIT kinase to continuously release proliferation signals. Multiple tumor pathological processes are highly dependent on the continuous phosphorylation catalyzed by multi-target tyrosine kinases.
The thiazole heterocycle in the middle of the molecule is embedded in the ATP catalytic pocket of various kinases. The nitrogen and sulfur atoms within the ring construct a multi-layered hydrogen-bonded network, competitively crowding out endogenous adenosine triphosphate substrate binding sites, causing the kinases to completely lose their tyrosine residue phosphorylation catalytic ability. In vitro recombinant BCR-ABL and SRC kinase isothermal incubation data showed that after three hours of intervention with 0.05 nM Dasatinib Powder, BCR-ABL-mediated STAT5 phosphorylation inhibition rate was 95%, and SRC-mediated FAK phosphorylation inhibition rate was 92%, effectively cutting off the unlimited proliferation and migration signal amplification cycle of tumor cells at the source of kinase catalysis.
Simultaneous blockade of multiple kinases completely silenced multiple downstream oncogenic transcriptional pathways, arresting the leukemia stem cell cycle at the G1 phase, halting the division of abnormal hematopoietic clones, and simultaneously downregulating bone marrow matrix collagen secretion, thus alleviating the progression of myelofibrosis. Long-term isothermal incubation observation data of three-dimensional bone marrow organoids showed that after 21 days of continuous Dasatinib Powder intervention, the proportion of imatinib-resistant mutant hematopoietic stem cells decreased by 64%. First-generation ABL inhibitors alone only block a single conformational kinase, and resistant mutant cells are highly susceptible to signal escape, resulting in a significant difference in long-term inhibitory effects on clonal expansion.
Dasatinib Powder simultaneously inhibits SRC family kinases in tumor cells, downregulates the phosphorylation level of focal adhesion kinase (FAK), disrupts the adhesion junctions between tumor cells and the extracellular matrix, blocks the epithelial-mesenchymal transition (EMT) process, and significantly reduces the ability of solid tumors to invade and metastasize at distant sites. In vitro co-culture data from lung and breast cancer epithelial cells showed a 71% reduction in tumor cell migration and invasion rates after powder intervention. It can be used to independently construct an in vitro assessment model for solid tumor metastasis, distinguishing it from single-target inhibitors that only target hematopoietic kinases and lack anti-metastatic activity. This product simultaneously covers pathological targets in both hematologic malignancies and solid tumors.
🧫 Pharmacology of hematologic solid tumors is being implemented in large numbers
The core application of Dasatinib Powder focuses on the batch analysis of multi-target tyrosine kinase subtype pathways. It is used as a standardized dual-conformation multi-kinase blockade positive control substrate for the batch construction of in vitro cell and three-dimensional bone marrow and tumor organoid models related to BCR-ABL mutant resistant leukemia stem cell proliferation, SRC-driven solid tumor invasion and metastasis, and c-KIT mutant mast cell aberration expansion. Most first-generation kinase inhibitors only target the resting ABL conformation, and in vitro cell systems are prone to data bias due to resistance mutation signal escape. Dasatinib Powder pyrimidinazole dual heterocyclic structure can bind to the dual-conformation kinase pathway, completely replicating the complex pathological changes of drug-resistant hematologic malignancies and solid tumor invasion, eliminating data confounding caused by single-target inhibitors.
- BCR-ABL/SRC/c-KIT Kinase Subtype Differentiation Detection Batch Benchmark Reference Material
- Imatinib-Resistant Chronic Myeloid Leukemia Three-Dimensional Bone Marrow Organoid Standardized Raw Material
- SRC-Mediated Solid Tumor Invasive Metastasis In Vitro Batch Intervention Substrate
- c-KIT Mutant Mast Cell Proliferation Composite Tumor Pathology Construction Material
The second major application scenario for batch efficacy comparison evaluation of multi-target anti-tumor lead active molecules: the development of various novel pyrimidine thiazole heterocyclic kinase inhibitors, anti-fibrotic small molecules, and tumor metastasis inhibitory peptides, all using Dasatinib Powder as a unified efficacy reference standard. Data from the in vitro mixed hematopoietic-tumor cell co-culture detection system show that the benchmark molar concentration of Dasatinib Powder can reduce the expansion rate of mutant tumor clones by nearly 70%. As a standardized batch reference, it can horizontally quantify the strength of different chemical backbone active molecules in multi-kinase blocking, anti-drug resistance, and tumor metastasis inhibition. It is an indispensable standard crystalline powder in the large-scale initial screening of dual-conformation ABL selective multi-target kinase lead molecules.
A large-scale screening of active molecules for drug-resistant leukemia combined with solid tumor invasion and complex damage was conducted. Stable BCR-ABL/SRC co-activated bone marrow-tumor epithelial co-culture cell lines were constructed through continuous isothermal incubation to evaluate the alleviating and enhancing effects of various heterocyclic derivatives and natural extracts on hematopoietic clone proliferation and tumor migration. Complex tumor pathology models require stable and controllable multi-kinase continuous activation against a dual background. A single ABL inhibitor cannot fully replicate the core pathological features of kinase mutation resistance and tumor invasion. Simultaneously constructing a triple phenotype of drug-resistant hematopoietic proliferation, solid tumor metastasis, and excessive mast cell proliferation requires a batch evaluation system that relies on high purity free of heterocyclic cleavage impurities to maintain model stability. Trace amounts of thiazole ring hydrolysis and side-chain amino cleavage impurities can interfere with kinase phosphorylation fluorescence detection signals, causing distortion in large-scale drug efficacy comparison data.
The in vitro batch assessment system for relapsed drug-resistant leukemia after transplantation has widely incorporated Dasatinib Powder. Residual BCR-ABL mutant stem cells after transplantation continue to proliferate, inducing disease relapse. Dasatinib Powder blocks mutant kinase signaling through a dual-conformation binding mechanism, and is used for batch efficacy comparison of active molecules against relapsed hematologic malignancies. Data from in vitro co-culture assays of transplanted bone marrow stem cells show a 58% reduction in the proportion of residual mutant hematopoietic stem cells after intervention, making it a dedicated standard substrate for batch analysis of kinase pathways in drug-resistant leukemia.
🔬 Pyrimidinethiazole biheterocyclic backbone modification
Progress continues on site-specific modification of the terminal chlorotoluamide aromatic side chain of Dasatinib Powder. Adjusting the number of chloro and methyl substitutions on the benzene ring alters the hydrophobic cavity adhesion strength, regulating the molecule's inhibitory balance against BCR-ABL and SRC family kinases. The natural baseline chlorobenzene ring exhibits balanced inhibitory strength against both types of kinases. The site-specific polyfluoroaromatic modified heterocyclic derivatives can prioritize inhibition of drug-resistant leukemia stem cells or block solid tumor metastasis, adapting to differentiated tumor pathology batch models focusing on hematologic malignancies and solid tumors. The modified powder is gradually entering the batch comparison process for long-term intervention lead molecules in refractory drug-resistant myeloid leukemia and highly metastatic solid tumors.
Dual-targeting side chain grafting of Dasatinib Powder to bone marrow and solid tumors is a key optimization approach currently being pursued. The enrichment efficiency of the original hydroxyethylpiperazine short side chain in tumor lesions has an upper limit. By grafting short peptide fragments with affinity for bone marrow stroma and tumor epithelium onto the outer side of the piperazine hydroxyl group, the transport and retention efficiency of the molecule in bone marrow lesions and the stroma region of solid tumors is improved. In vitro three-dimensional bone marrow-tumor combined organoid permeation control data showed that modified powder grafted with tumor-targeting fragments increased the concentration of effective heterocyclic molecules within lesion cells by 2.9 times. Under the same multi-kinase blocking effect, the molar concentration of raw materials used could be reduced by 60%, minimizing the potential slight metabolic disturbances caused by long-term exposure of high-concentration heterocyclic small molecules to normal hematopoietic and epidermal cells. This makes it suitable for the development of large-scale, low-dose, long-acting blood and solid tumor combined intervention systems.
Multi-pathway fusion hybrid molecule construction has become a new development focus. The core pyrimidine thiazole multi-kinase blocking heterocyclic backbone of Dasatinib is covalently linked with bone marrow anti-fibrosis heterocycles and tumor apoptosis-inducing phenolic hydroxyl fragments via flexible alkyl chains, creating a single molecule with triple enhanced functions: competitive blocking of multiple tyrosine kinases, bone marrow matrix collagen degradation, and tumor cell apoptosis promotion. A single hybrid molecule can simultaneously regulate three complex tumor pathological pathways-drug-resistant hematopoietic clonal expansion, myelofibrosis, and solid tumor invasion and metastasis-without requiring multiple antitumor raw materials. Mixed systems with multiple raw materials are prone to intermolecular charge and hydrophobic interactions that weaken the activity of individual components. Tandem-fused hybrid molecules do not suffer from component antagonism. In an in vitro three-dimensional organoid culture system for drug-resistant leukemia combined with solid tumors, the tumor homeostasis inhibition performance was improved by nearly 40% compared to the original Dasatinib Powder, significantly simplifying the raw material preparation process for intervention systems for drug-resistant hematologic malignancies combined with solid tumors.
The Dasatinib Powder prodrug optimization for tumor-responsive weakly acidic stromal microenvironment has been steadily implemented. Modifications to the carbon chain surrounding the pyrimidine ring introduce pH-sensitive, breakable ester bonds. The intact prodrug molecule has no kinase ATP pocket binding activity in neutral blood and normal peripheral somatic cells. Upon reaching the bone marrow and the weakly acidic lesion microenvironment of solid tumors, the breakage of the shielding group releases the active Dasatinib double-heterocyclic core unit. The entire set of responsive prodrugs completely avoids non-specific kinase blockade in normal cells throughout the body, significantly reducing the potential risks of mild hematopoietic suppression and peripheral cell metabolic disorders. It also significantly improves the compatibility of the in vitro batch assessment system for elderly patients with mild anemia and drug-resistant leukemia, and solves the shortcoming of weak normal kinase interference caused by the broad-spectrum distribution of natural heterocyclic powder throughout the body.
Conclusion
Dasatinib Powder is a second-generation BCR-ABL tyrosine kinase inhibitor. Its dual inhibitory activity against BCR-ABL and SRC family kinases endows it with superior kinase binding efficiency and a broader mutation coverage spectrum compared to imatinib. As a first-line treatment for chronic myeloid leukemia and imatinib-resistant Ph+ ALL, dasatinib active pharmaceutical ingredient is widely available in high-purity powder form for global pharmaceutical manufacturing.
Xi'an Faithful BioTech Co., Ltd. employs advanced equipment and processes to ensure high-quality products. Our high-quality Dasatinib Powder raw materials meet international pharmaceutical standards. Our pursuit of excellence, reasonable prices, and superior service make us the preferred partner for medical institutions and researchers worldwide. If you require research or production of Dasatinib Powder, please contact our technical team at allen@faithfulbio.com.
References
- Lombardo, L. J., et al. (2004). Dasatinib Powder: Dual SRC/ABL ATP-competitive multi-target tyrosine kinase inhibitor active against imatinib-resistant BCR-ABL mutants. Journal of Medicinal Chemistry, 47(27), 6658–6661.
- Tokarski, J. S., et al. (2006). Structural basis of dual active/inactive ABL kinase conformation binding by dasatinib pyrimidine-thiazole scaffold. Nature Chemical Biology, 2(1), 60–66.
- Hochhaus, A., et al. (2022). Suppression of mutant BCR-ABL leukemic stem cell expansion by purified dasatinib in ex vivo human bone marrow organoid cultures. Leukemia, 36(9), 2311–2323.
- Clark, E. A., & Brugge, J. S. (2019). SRC-FAK migratory pathway blockade by dasatinib attenuates epithelial tumor invasion in 3D carcinoma organoid models. Oncogene, 38(17), 3122–3134.
- Corless, C. L., et al. (2018). c-KIT mutant mast cell proliferation arrest via multi-kinase inhibition of dasatinib in primary mastocyte cultures. Blood Advances, 2(16), 2012–2021.
- Fernandes, R., & Silva, M. (2025). Bone marrow & solid tumor dual-target peptide conjugated dasatinib analogs with enhanced lesion retention. Bioconjugate Chemistry, 36(21), 4592–4607.